From TechCrunch · Julie Bort · · 1m
OpenAI buys Orchestra Bio to expand biotech AI
OpenAI acquires AI drug-discovery startup Orchestra Bio and folds its team into Rosalind, its life sciences research model.
In brief
OpenAI acquires AI drug-discovery startup Orchestra Bio and folds its team into Rosalind, its life sciences research model. OpenAI acquired biotech startup Orchestra Bio on Tuesday to strengthen its Rosalind AI model for life sciences research, which already counts Moderna and Novo Nordisk as customers. Originally…
OpenAI acquires Orchestra Bio
OpenAI acquired four-year-old AI biotech software startup Orchestra Bio on Tuesday. The company had raised around twenty million dollars as of twenty twenty-five from backers including Andreessen Horowitz, Atria, and eight VC.
What Orchestra Bio does
Orchestra creates AI agents that help biotech companies manage drug-discovery operations, from tracking finances to resolving scheduling issues with clinical trials.
Integration with Rosalind
OpenAI is adding Orchestra's team and technology to Rosalind, its AI model for life sciences research, and to Rosalind Workbench, a tool that helps researchers plan experiments and analyze results.
AI labs absorbing startups
The acquisition shows how the biggest AI labs, namely OpenAI and Anthropic, are building software for major industries like pharma.
The essence
OpenAI acquired biotech startup Orchestra Bio on Tuesday to strengthen its Rosalind AI model for life sciences research, which already counts Moderna and Novo Nordisk as customers.
